Zobrazeno 1 - 10 of 183 pro vyhledávání: '"Alexander McGregor"'
3
Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy
Autor: Karl H. Tully, Quoc-Dien Trinh, Joachim Noldus, Maxine Sun, Adam S. Kibel, Bradley Alexander McGregor, Peter Herzog, Shehzad Basaria, David-Dan Nguyen, Paul L. Nguyen, Ginger Jin
Publikováno v: European Urology Oncology. 4:66-72
Previous studies have found an association between androgen deprivation therapy (ADT) and an increased risk of dementia and depression in elderly men. This association remains controversial, and little is known about the effects of ADT in younger men
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9588051235bef98156bfcb7623cba668
https://doi.org/10.1016/j.euo.2019.08.003
Zobrazit plný text záznamu
4
Tissue Based Biomarkers for Metastatic Clear Cell Renal Carcinoma: A Systematic Review
Autor: Bradley Alexander McGregor, Andrew Schmidt, Paul A. Bain
Publikováno v: Kidney Cancer. 4:197-210
Background: Treatments for metastatic clear cell renal carcinoma (mccRCC) are evolving with multiple targeted and immune therapy drugs currently approved by regulatory agencies as single agents or in combination. Developing predictive biomarkers to d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a5a04d0371cf8043d35e07823b52515b
https://doi.org/10.3233/kca-200103
Zobrazit plný text záznamu
5
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
Autor: Rana R. McKay, Lauren C. Harshman, David F. McDermott, Benjamin L. Maughan, Tracy L. Rose, Christos Kyriakopoulos, Bradley Alexander McGregor, Toni K. Choueiri, Walter M. Stadler, Yousef Zakharia, David A. Braun, Xiao Wei, Wanling Xie
Publikováno v: J Clin Oncol
PURPOSE In this phase II response-adaptive trial, we investigated the rational application of immune checkpoint blockade in renal cell carcinoma (RCC; ClinicalTrials.gov identifier: NCT03203473 ). METHODS We enrolled patients with metastatic RCC with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ab5413583214482f6b3dd40cfebae0
https://doi.org/10.1200/jco.20.02295
Zobrazit plný text záznamu
7
Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors
Autor: Arwa A. Alzaghal, Guru Sonpavde, Francesco Alessandrino, Atul B. Shinagare, Amin Nassar, Arvind Ravi, Rahul Gujrathi, Bradley Alexander McGregor
Publikováno v: European Urology Oncology. 3:680-686
Reliable biomarkers to predict the response of metastatic urothelial cancer (mUC) to programmed death-1 and programmed death-ligand 1 (PD-1/PD-L1) inhibitors are being investigated. Texture analysis represents tumor heterogeneity and may serve as a p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bbe8d438d3b4c5139c279ed7ea5c55f
https://doi.org/10.1016/j.euo.2019.02.002
Zobrazit plný text záznamu
8
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases
Autor: Grace Shaw, Christopher Sweeney, Edoardo Francini, Li Zhang, Kathryn P. Gray, Bradley Alexander McGregor, Carolyn Evan
Publikováno v: Prostate Cancer and Prostatic Diseases. 24:341-348
In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent skeletal related events (SREs) is unkn
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eff2b72949706db1c45cee653041051c
https://doi.org/10.1038/s41391-020-00280-6
Zobrazit plný text záznamu
9
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma
Autor: Toni K. Choueiri, Amin Nassar, Pier Vitale Nuzzo, Marina D. Kaymakcalan, David A. Braun, Mehmet Asim Bilen, Sarah Abou-Alaiwi, Dylan J. Martini, John A. Steinharter, Ziad Bakouny, Justin H. Fleischer, Aly-Khan A. Lalani, Xiao X. Wei, Wanling Xie, Bradley Alexander McGregor, Lauren C. Harshman
Publikováno v: European Journal of Cancer. 135:203-210
Background Cabozantinib is approved for the first and subsequent line treatment of metastatic clear-cell renal cell carcinoma (ccRCC) based on trials in which most patients were immune checkpoint blockade (ICB) naive. With an expanding role of ICB in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fd0985c61010370cd4f2e6a86b6e4e0
https://doi.org/10.1016/j.ejca.2020.05.009
Zobrazit plný text záznamu
10
Antibody–drug conjugates for the treatment of urothelial carcinoma
Autor: Bradley Alexander McGregor, Praful Ravi
Publikováno v: Expert Opinion on Biological Therapy. 21:915-922
The therapeutic landscape for urothelial carcinoma has changed significantly over the past few years with the addition of immunotherapy to platinum-based chemotherapy. Targeted therapy against FGFR (fibroblast growth factor receptor) is now also appr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8cfd3a8a10ea8582abd18b48ce3c059
https://doi.org/10.1080/14712598.2020.1789096
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje